ResearcherSichuan UniversityActive in the last 2 years
Shuangshuang Li
Matched on ORCID iD 0000-0001-5887-2280; OpenAlex author ID A5100653004. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2020: 2 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper
Papers 4
- [The Value of Clinical Characteristics and Hematological Parameters for Prognostic Assessment of Pancreatic Cancer Patients Undergoing Radical Resection]. First author DOI 10.12182/20240560604↗
- The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-021-02972-6↗
- ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/md.0000000000019413↗
- Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Ad… Co-author DOI 10.3389/fimmu.2020.01127↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Lianli Zeng · 1 shared paper, 2024 · strength 0.31
- Cheng Yi · 1 shared paper, 2024 · strength 0.31
- Yi Cheng · 2 shared papers, 2020–2021 · strength 0.23
- Paper The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanc… DOI 10.1186/s12967-021-02972-6↗
- Paper Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Pati… DOI 10.3389/fimmu.2020.01127↗
- Dan Cao · 2 shared papers, 2020–2021 · strength 0.23
- Paper The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanc… DOI 10.1186/s12967-021-02972-6↗
- Paper Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Pati… DOI 10.3389/fimmu.2020.01127↗
- Lin Shui · 2 shared papers, 2020–2021 · strength 0.23
- Paper The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanc… DOI 10.1186/s12967-021-02972-6↗
- Paper Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Pati… DOI 10.3389/fimmu.2020.01127↗
- Heli Gao · 1 shared paper, 2021 · strength 0.12
- Li Mao · 1 shared paper, 2021 · strength 0.12
- Ang Li · 1 shared paper, 2021 · strength 0.12
- Ning An · 1 shared paper, 2021 · strength 0.12
- Bole Tian · 1 shared paper, 2021 · strength 0.12
- Ningna Weng · 1 shared paper, 2020 · strength 0.11
- Congya Zhou · 1 shared paper, 2020 · strength 0.11
- Ke Cheng · 1 shared paper, 2020 · strength 0.11
- Qing Zhu · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.